INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10522497
Filing Date		2005-09-07
First Named Inventor	Philip	pe Bernard
Art Unit		1624
Examiner Name	Not Y	et Assigned
Attorney Docket Number		REGIM 3.3-048

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	Name of Pate of cited Docu	entee or Applicant Iment	Releva	Columns,Lines whe Int Passages or Rel s Appear	
/VB/	1	3910907		1975-10	)-07	O'Brien et al.				
/VB/	2	3995039		1976-11	1-30	Rooney et al.				
/VB/	3	4183930		1980-01	I-15	Cohen et al.				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Examiner No Publication Number Kind Code <sup>1</sup> Publication Date Name of Patentee or Applicant of cited Document Pages, Columns, Lines who Relevant Passages or Rel Figures Appear									
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ade	d button	Add	
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Kind Code <sup>2</sup> j Code <sup>4</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	T5	
/VB/	1	269859	EP			1988-06-08	Otsuka Pharma Co	Ltd		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10522497	
Filing Date		2005-09-07	
First Named Inventor	Philip	ppe Bernard	
Art Unit		1624	
Examiner Name	Not Y	et Assigned	
Attorney Docket Number		REGIM 3.3-048	

/VB/	2	1515107	EP		2005-03-16	Lg Electronics Inc		
	3	2230366	FR		1974-12-20	Sandoz Sa		
	4	2818278	FR		2002-06-21	Sod Conseils Rech Applic		X
	5	00/59907	wo		2000-10-12	Du Pont Pharm Co		
	6	01/23388	wo		2001-04-05	Neurogen Corp et al.		
	7	02/50079	wo		2002-06-27	SOD CONSEILS RECH APPLIC		
	8	02/72202	wo		2002-09-19	Bristol Myers Squibb Pharma Co		
	9	98/03510	wo		1998-01-29	Du Pont Merck Pharma		
/VB/	10	99/38868	wo		1999-08-05	Du Pont Pharm Co		
If you wis	h to a	dd additional For	eign Patent Documer	nt citation	information p	please click the Add button	Add	
			NON-PATE	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	(book, magazin		iposium,	catalog, etc),	f the article (when appropri date, pages(s), volume-iss		T5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10522497
Filing Date		2005-09-07
First Named Inventor	Philip	pe Bernard
Art Unit		1624
Examiner Name	Not Y	et Assigned
Attorney Docket Numb	er	REGIM 3.3-048

/VB/	1	Ballard, A.S., Gingell, C.J., Tang, K., Turner, L.A., PRICE, M.E. (J. Urol, 1998, 159, 2164-2171)	
	2	Estevez A.G. et al. (J. Neurosci. 1998, 18(3), 923-931)	
	3	Rathbone, M.P. et al. Prog. Neurobiol. (1999), 59, 663-690)	
	4	Sanga et al, J. Med. Chem. 1982, 25, 243-249	
	5	Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S.C. and Dinarello, C.A. (Blood, 1990, 75, 40-47)	
	6	Torphy, T.J., Zhou, H.L. and Cieslinski, L.B. (J. Pharmacol. Exp. Ther., 1992, 263, 1195-1205)	
7	7	Weishaar, R.E., Burrows, S.D., Kobylarz, D.C., Quade, M.M. and Evans, D.B. (Biochem. Pharmacol., 1986, 35, 787-800)	
	8	Perez-Torres, S. et al., J. Chem. Neuroanatomy, 2000, 20, 349-374)	
	9	ROBINS R K ET AL: "PURINE ANALOG INHIBITORS OF XANTE IINE OXIDASE - STRUCTURE ACTIVITY RELATIONSHIPS AND PROPOSED BINDING OF THE MOLYBDENUM COFACTOR" JOURNAL OF HETEROCYCLIC CHEMISTRY. HETEROCYCNATION. PROVO. LIS, vol. 22, 1 May 1785 (1865-65-01). pages 001-634.	
	10	RABOISSON, PIERRE EI AL: "A General Approach toward the Synthesis of C-Nucleoside Pyrazolo[1,5-a]-1,3,5-tiazines and Their 3',5'-Bisphosphate 0-Nucleotide Analogues as the First Reported in Vivo Stable P2Y1-Receptor Antagonists' JOURNAL OF ORGANIC CHEMISTRY (2002), 67(23), 8063-8071	
/VB/	11	Nicholson C.D., JACKMAN S.A. and WILKE R. (Brit. J. Pharmacol. 1989, 97, 889-897)	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10522497
Filing Date		2005-09-07
First Named Inventor	Philip	pe Bernard
Art Unit		1624
Examiner Name	Not Yet Assigned	
Attorney Docket Number		PECIM 3 3.048

/VB/ 12 Cassina P. et al. (J. Neurosci. Res. 2002 67(1): 21-9)						
If you wis	h to a	dd add	ditional non-patent literature document citation info	rmation please click the Add b	utton Add	
			EXAMINER SIGNA	TURE		
Examiner Signature /Venkataraman Balasubramanian/ Date Considered				05/13/2008		
*EYAMIN	ER: In	itial if	reference considered whether or not citation is in	conformance with MPEP 609	Draw line through a	

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if Emplish lanquage translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.